Go to course page

Use of SGRT in SBRT: can we possibly reduce margin expansion and treatment related toxicity?

 

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute/Southeast Radiation Oncology Group

 

Go to previous session Go to next session